Alector, Inc. (ALEC) News
Follow Alector, Inc. (ALEC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Alector Agrees to 36.6 Million-Share Offering at $2.05 Each
Alector entered an underwriting agreement with Morgan Stanley and BTIG for a public offering of 36.6 million common shares. Gross proceeds are expected to be approximately $75.03 million before fees and expenses.
EQUITY | Oct 16, 2026, 08:53 PM UTC
M
Alector Prices $75 Million Share Offering; Stock Rises 6%
Alector priced an underwritten offering of 36.6 million common shares at $2.05 each. Its shares rose 6% to $2.03 in morning trading.
EQUITY | Oct 16, 2026, 01:48 PM UTC
M
Alector Prices 36.6 Million-Share Offering at $2.05
Alector priced an underwritten offering of 36.6 million shares at $2.05 per share, with expected gross proceeds of $75.03 million. The offering price is about 7.3% above the Oct. 15 close; closing is expected Oct. 19, su
EQUITY | Oct 16, 2026, 11:37 AM UTC
M
Roche Licenses Parkinson's Therapy From Alector For Up To $1.27B
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's disease treatment. Alector will receive $100 million upfront and potential future payments.
EQUITY | Oct 05, 2026, 12:06 PM UTC
M
Alector Licenses AL050 to Genentech for $100M Upfront
Alector granted Genentech exclusive global rights to develop and commercialize AL050. Alector will receive $100M upfront and is eligible for up to $1.17B in milestones, plus tiered royalties.
EQUITY | Oct 05, 2026, 11:02 AM UTC
M
Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental amyotrophic lateral sclerosis drug after a mid-stage study failed to meet its goals.
EQUITY | Sep 16, 2026, 04:51 PM UTC
L
ALEC: ABC platform advances five neurodegeneration drugs with strong preclinical data and 2027 milestones
The discussion highlighted a strategic pivot to a validated neurodegeneration pipeline, leveraging the ABC platform for efficient brain delivery of multiple drug modalities. Key programs, including AL137 and Tau siRNA, a
NEWS | Sep 15, 2026, 12:53 PM UTC
L
ALEC: Diversified neurodegeneration pipeline advances with ABC platform, AI-driven efficiency, and strong cash runway
The discussion highlighted a strategic pivot to a diversified, validated neurodegeneration pipeline, leveraging the ABC platform for efficient brain delivery of multiple modalities. AI and outsourcing drive operational e
NEWS | Sep 15, 2026, 11:59 AM UTC
M
AL137 lead anti-Aβ antibody enters Phase I trials
Neurodegeneration-focused company ALEC is advancing its blood-brain barrier platform. Its lead anti-Aβ antibody AL137 has entered Phase I trials, while additional siRNA and enzyme therapies are progressing toward the cli
EQUITY | Sep 10, 2026, 07:07 PM UTC
L
ALEC - Alector to Participate in Upcoming Healthcare Conferences
ALEC - Alector to Participate in Upcoming Healthcare Conferences
EQUITY | Sep 03, 2026, 08:08 PM UTC